We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

176 hedge funds and large institutions have $1.39B invested in Five Prime Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 65 increasing their positions, 65 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

37% more capital invested

Capital invested by funds: $1.01B → $1.39B (+$373M)

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

4% more funds holding

Funds holding: 170176 (+6)

0% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 65

94% less call options, than puts

Call options by funds: $380K | Put options by funds: $6.85M

Holders
176
Holders Change
+6
Holders Change %
+3.53%
% of All Funds
4.7%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
27
Increased
65
Reduced
65
Closed
20
Calls
$380K
Puts
$6.85M
Net Calls
-$6.47M
Net Calls Change
-$1.55M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
26
Perceptive Advisors
New York
$8.74M -$140K -2,930 -2%
RSCM
27
Rock Springs Capital Management
Maryland
$8.73M +$633K +13,250 +9%
Wells Fargo
28
Wells Fargo
California
$8.27M +$531K +11,111 +8%
PAMU
29
Pictet Asset Management (UK)
United Kingdom
$8.23M +$7.48M +156,719 New
Capital Fund Management (CFM)
30
Capital Fund Management (CFM)
France
$8.07M +$7.34M +153,680 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$7.58M -$220K -4,603 -3%
JP Morgan Chase
32
JP Morgan Chase
New York
$6.81M +$2.35M +49,146 +61%
HSA
33
Hussman Strategic Advisors
Maryland
$6.56M +$5.97M +125,000 New
HA
34
Hays Advisory
Tennessee
$6.46M -$600K -12,574 -9%
MCM
35
Matarin Capital Management
New York
$6.16M +$3.86M +80,898 +222%
DCM
36
Driehaus Capital Management
Illinois
$6.07M -$968K -20,261 -15%
Lord, Abbett & Co
37
Lord, Abbett & Co
New Jersey
$5.93M -$3.98M -83,288 -42%
BIM
38
BlackRock Investment Management
Delaware
$5.75M +$35.8K +750 +0.7%
AllianceBernstein
39
AllianceBernstein
Tennessee
$5.66M +$1.16M +24,250 +29%
Skandinaviska Enskilda Banken (SEB)
40
Skandinaviska Enskilda Banken (SEB)
Sweden
$5.2M +$4.73M +99,100 New
Deutsche Bank
41
Deutsche Bank
Germany
$5.18M -$1.91M -40,040 -29%
Zurich Cantonal Bank
42
Zurich Cantonal Bank
Switzerland
$5.09M +$849K +17,770 +22%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$4.62M +$750K +15,716 +22%
AIC
44
AWM Investment Company
New York
$4.2M -$478K -10,000 -11%
CS
45
Credit Suisse
Switzerland
$4.03M +$589K +12,325 +19%
SIM
46
Spark Investment Management
New York
$3.85M -$3.57M -74,700 -50%
GCP
47
GSA Capital Partners
United Kingdom
$3.73M -$1.12M -23,425 -25%
VIA
48
Vident Investment Advisory
Georgia
$3.44M +$2.34M +48,935 +295%
Mackenzie Financial
49
Mackenzie Financial
Ontario, Canada
$3.4M +$3.1M +64,873 New
TAM
50
Trillium Asset Management
Massachusetts
$3.35M +$67.8K +1,419 +2%

FPRX Hedge Fund Activity: Q3 2016 in Review

176 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2016, worth a combined $1.39B — up 37% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new FPRX positions and 20 closed out — a net gain of 7 holders — while 65 added to existing stakes and 65 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $68.5M. The largest seller was Wellington Management Group, cutting an estimated $15.4M.

  • 176 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2016, up from 170 in Q2 2016.
  • Funds reported $1.39B of Five Prime Therapeutics, Inc. stock for Q3 2016, up 37% quarter-over-quarter.
  • 27 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2016 and 20 closed out, a net change of +7 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q3 2016 was Fidelity Investments, an estimated $68.5M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q3 2016 was Wellington Management Group, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2016.